EstBAN has invested up to €200k in SafePAS and up to €50k in BrachyDOSE, two innovative startups addressing key challenges in diagnostics and cancer treatment, respectively.

Target Company Information

SafePAS, a groundbreaking startup, has developed portable devices capable of delivering lab-accurate testing results on-site, significantly reducing costs compared to traditional laboratory methods. Their innovative offerings include Drug Hunter, which facilitates rapid drug detection, and SMAGRY, which is focused on enhancing soil health analytics. By catering to a diverse clientele that includes law enforcement agencies and agricultural stakeholders, SafePAS is poised to transform the landscape of real-time field diagnostics.

On the other hand, BrachyDOSE addresses the critical challenge of radiation-related injuries during cancer treatment through its hardware-software solution. By employing AI-integrated sensors, BrachyDOSE collects real-time patient data to ensure that radiation doses are always in alignment with prescribed treatment plans. Their efforts are aimed at reducing the likelihood of treatment errors, lowering hospital expenses, and ultimately enhancing patient outcomes. The company boasts established partnerships with hospitals across Lithuania, Estonia, and Germany.

Industry Overview in Estonia

Estonia's startup ecosystem has gained considerable traction over recent years, bolstered by its strategic location, advanced digital infrastructure, and supportive government policies. The nation is recognized as a hub for inno